Introduction — Granules India Delivers a Strong Q2 Performance

Granules India has released its Q2 FY2025-26 (July–September 2025) financial results, and the numbers tell a clear story:
broad-based revenue growth, stronger margins, rising demand in Europe & North America, and improved overall profitability.

The company registered healthy performance across APIs, Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FDF) categories. With higher volumes and improving realizations, Granules India closed one of its strongest quarters in recent years.

Here are the verified headline numbers for Q2 FY2025-26:

• Revenue from Operations: ₹12,969.88 million (≈ ₹1,296.99 crore)

• Net Profit (PAT): ₹1,306 million (≈ ₹130.6 crore)

• EBITDA: ₹2,782 million

• YoY Revenue Growth: ~34%

• YoY PAT Growth: ~34%

This performance reflects strong demand recovery in export markets, better product mix, and improved plant utilization.

Revenue Analysis — Strong Growth Across API & Formulations

Granules India’s revenue of ₹1,296.99 crore in Q2 FY26 marks a strong 34% YoY jump, driven by robust demand and higher volumes across:

✔ Finished Dosage (FDF)

Granules saw stronger offtake in the US and Europe. These high-volume formulations delivered better margins, pushing overall profitability.

✔ API Division

Being one of the world’s largest paracetamol producers, Granules benefitted from stable paracetamol shipments and rising export demand. Other APIs also saw increased order flow.

✔ Pharmaceutical Formulation Intermediates (PFI)

PFI registrations and orders from European partners contributed to revenue stability, helping the company compensate for any cyclical weakness in specific APIs.

The company’s diversified API + PFI + FDF model remains its biggest strength, insulating revenue from volatility in any single product line.

Profitability — Margin Expansion Shows Real Improvement

A key highlight of Q2 FY26 is the smart recovery in margins.

✔ Net Profit rises to ₹130.6 crore

This ~34% YoY PAT growth reflects strong operational recovery.

✔ EBITDA climbs to ₹2,782 million

EBITDA margin improves significantly due to cost optimization and better product mix.

✔ Operational efficiency plays major role

Manufacturing plants, including the critical Gagillapur facility, delivered better utilization and efficiency.

Granules benefited from:

• Higher contribution of formulations

• Better currency realization

• Improved capacity usage

• Reduction in overhead and inventory-related burdens

This margin improvement strengthens the company’s financial stability going into FY2026.

Management Guidance — Outlook Remains Cautiously Positive

Granules India’s management provided clear and practical guidance for the upcoming quarters. Their tone was optimistic but cautious, recognizing the opportunities in export markets while acknowledging industry challenges.

🔵 1. Strong Demand Expected from North America & Europe

The company expects sustained demand for both APIs and formulations in regulated markets.

🔵 2. Higher-Margin Formulations Will Be the Focus

Management plans to expand finished dosage capacity and reduce dependence on low-margin APIs.

🔵 3. Regulatory Compliance is a Top Priority

Having navigated past compliance issues, Granules is reinforcing plant-level quality systems.

🔵 4. Improvement in Working Capital Efficiency

The company aims to reduce inventory days and strengthen cash flows.

🔵 5. Pricing Pressure Still a Risk

APIs like paracetamol are global commodities; management is aware of potential price fluctuations.

🔵 6. Investment in Expansion Will Continue

Granules will selectively invest in capacity upgrades and modernization.

Overall, the leadership expects steady revenue growth and stable-to-improving margins for the remainder of FY26.

Business Drivers — What Powered Granules India This Quarter

✔ Stronger Exports in US & EU Markets

These markets contributed significantly to Q2 growth, with higher order flow and improved realizations.

✔ Recovery in API Business

After a period of price and regulatory pressure, API exports showed signs of recovery.

✔ Improved Product Mix

A heavier tilt toward formulations boosted margins.

✔ Operational Discipline

Manufacturing smoothness and plant-level efficiency helped EBITDA performance.

✔ Better Currency Realizations

Export-heavy companies like Granules benefit from favourable INR-USD trends.

Risks & Challenges — What Investors Must Watch

While Q2 performance is strong, a few risks remain:

⚠ API Price Volatility

Granules’ dependence on paracetamol APIs exposes it to commodity cycles.

⚠ Regulatory Inspections

Any adverse USFDA or EU regulatory note can temporarily disrupt production.

⚠ Working Capital Pressure

With export-driven growth, receivables and inventory levels must remain controlled.

⚠ Global Competition

Low-cost competition from other Asian markets can pressure pricing in APIs.

Despite these risks, Granules’ strong Q2 results demonstrate progress in building a more stable earnings base.

Earnings Comparison Table — Q2 FY26 vs Q1 FY26 vs Q2 FY25

Key Insights From the Table:

• Revenue jumped 34% YoY (₹966.6 crore → ₹1,296.9 crore)

• PAT jumped 34% YoY, reflecting margin recovery

• Sequential profit growth also improved (Q1 → Q2), signaling momentum

Conclusion — Granules India Strengthens Its Growth Story

Granules India’s Q2 FY2025-26 performance highlights:

• Strong earnings rebound

• Margin expansion

• North America & Europe-led growth

• Improved product mix

• Strategic operational efficiency

• Solid management guidance

This quarter reflects Granules’ shift toward more sustainable, higher-quality earnings powered by formulations and export strength. The pharma company still faces risks around pricing and regulatory environments, but Q2 results show that it is better prepared and more stable than before.

For investors and industry followers, Granules India is clearly a company that is moving into a stronger phase of growth, backed by improved profitability, better operations, and a clearer long-term strategy.